Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

September 5, 2025

Study Completion Date

September 10, 2025

Conditions
DM1Muscular DystrophiesMyotonic DystrophyMyotonic Dystrophy 1Myotonic DisordersMuscular Disorders, AtrophicMuscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesGenetic Diseases, InbornHeredodegenerative Disorders, Nervous SystemNeurodegenerative Diseases
Interventions
DRUG

Placebo

Placebo will be administered by intravenous (IV) infusion.

DRUG

AOC 1001

AOC 1001 will be administered by intravenous (IV) infusion.

Trial Locations (8)

14642

University of Rochester Medical Center, Rochester

23298

Virginia Commonwealth University, Richmond

32608

University of Florida, Gainesville

43221

Ohio State University, Columbus

66205

Kansas University Medical Center, Kansas City

80045

University of Colorado, Denver

90095

University of California Los Angeles, Los Angeles

94304

Stanford University, Palo Alto

Sponsors
All Listed Sponsors
lead

Avidity Biosciences, Inc.

INDUSTRY